What Is MOTS-c?
MOTS-c (Mitochondrial ORF of 12S rRNA Type-c) is classified as a mitochondrial peptide peptide. Regulates mitochondrial function and AMPK. Enhances glucose uptake and fatty acid oxidation, improves insulin sensitivity, and protects against age-related metabolic decline.
It is extensively evaluated in laboratory and clinical settings for its potential to drive energy, metabolism, fat loss, longevity. Researchers target MOTS-c for its ability to interact with specific cellular and molecular pathways, making it a compound of significant interest across multiple therapeutic domains.
Promising but limited human data. As an endogenous peptide, theoretical biocompatibility favorable.
How Does MOTS-c Work?
Regulates mitochondrial function and AMPK. Enhances glucose uptake and fatty acid oxidation, improves insulin sensitivity, and protects against age-related metabolic decline.
At the molecular level, MOTS-c operates through pathways characteristic of the Mitochondrial Peptide class. By interacting with target receptors and downstream signaling cascades, the compound initiates biological responses associated with energy, metabolism, fat loss, longevity.
Expected Research Timeline
Weeks 2–4
Enhanced exercise performance and endurance; reduced muscle fatigue
Months 2–3
Metabolic adaptations; improved body composition
Long-Term
Mitochondrial health optimization; age-related metabolic protection
What Does the Research Say?
The following are key findings from peer-reviewed studies on MOTS-c, indexed on PubMed and equivalent databases:
[1]MOTS-c regulates metabolic homeostasis (Cell Metabolism)
Lee et al. (Cell Metabolism): Discovery paper showing MOTS-c is a mitochondrial-derived peptide that regulates insulin sensitivity and metabolic homeostasis via AMPK activation.
Evidence: emerging[2]MOTS-c prevents age-related insulin resistance in mice
Lee et al.: MOTS-c treatment prevents both age-dependent and high-fat-diet-induced insulin resistance and diet-induced obesity in mouse models.
Evidence: preclinical[3]MOTS-c improves skeletal muscle glucose metabolism
Study demonstrating MOTS-c specifically targets skeletal muscle glucose metabolism, providing molecular basis for metabolic benefits and exercise-mimetic properties.
Evidence: preclinical[4]Circulating MOTS-c levels decline with age and obesity
Human observational study linking decreased circulating MOTS-c levels with aging, obesity, and type 2 diabetes suggesting therapeutic rationale for supplementation.
Evidence: emergingSafety & Side Effects
Promising but limited human data. As an endogenous peptide, theoretical biocompatibility favorable.
| Side Effect | Incidence | Severity |
|---|---|---|
| Injection site reaction | ~5% of users | mild |
| Generally well-tolerated | Very limited human data | mild |
FDA Status: Not Approved for Human Therapeutic Use
MOTS-c is not currently FDA-approved for human use. It is available for research purposes only. Always consult a licensed healthcare provider.
How Is MOTS-c Used?
Route
SubQ
Dose Range
2000–2000 mcg
Frequency
5x/week
Cycle
8–8 wk
Timing: Morning or pre-exercise
Notes: Exercise-mimetic. Often taken pre-workout. Higher doses used in research.
All dosing information reflects parameters reported in published research literature and is not intended as clinical guidance. Usage of any peptide should be supervised by a qualified healthcare professional.
MOTS-c vs. Related Compounds
Where to Source MOTS-c for Research
Purchasing ultra-high purity, laboratory-grade peptides is critical for verifiable research. We only recommend vendors providing independent, third-party HPLC Certificates of Analysis (COA).
Disclosure: PeptiDex may earn a commission from purchases. This does not affect our recommendations. We exclusively feature vendors that pass our strict quality verification protocols.
Frequently Asked Questions
What is MOTS-c?
MOTS-c is a mitochondrial peptide peptide. Regulates mitochondrial function and AMPK. Enhances glucose uptake and fatty acid oxidation, improves insulin sensitivity, and protects against age-related metabolic decline.
What are the primary research benefits of MOTS-c?
Published research identifies primary mechanisms targeting: Energy, metabolism, fat loss, longevity. These findings come from 4+ peer-reviewed studies indexed in our database.
What is the half-life of MOTS-c?
In published pharmacokinetic data, MOTS-c demonstrates a half-life of approximately 4 hours.
Is MOTS-c FDA approved?
MOTS-c is not currently FDA-approved for human therapeutic use. It is classified as a research compound and is studied under investigational protocols. Always consult a healthcare provider.
What are common side effects of MOTS-c?
Reported side effects in published literature include Injection site reaction (~5% of users), Generally well-tolerated (Very limited human data). Most are classified as mild in severity.
How is MOTS-c administered?
In research settings, MOTS-c is typically administered via SubQ. Exercise-mimetic. Often taken pre-workout. Higher doses used in research.
Sources
- MOTS-c regulates metabolic homeostasis (Cell Metabolism). View on PubMed
- MOTS-c prevents age-related insulin resistance in mice. View on PubMed
- MOTS-c improves skeletal muscle glucose metabolism. View on PubMed
- Circulating MOTS-c levels decline with age and obesity. View on PubMed